Trazodone composition for once a day administration
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/20
A61K-009/48
출원번호
UP-0519194
(2006-09-11)
등록번호
US-7829120
(2010-11-25)
발명자
/ 주소
Gervais, Sonia
Smith, Damon
Rahmouni, Miloud
Contamin, Pauline
Ouzerourou, Rachid
Ma, My Linh
Ferrada, Angela
Soulhi, Fouzia
출원인 / 주소
Labopharm Inc.
Labopharm Europe Limited
Labopharm (Barbados) Limited
대리인 / 주소
Goodwin Procter LLP
인용정보
피인용 횟수 :
6인용 특허 :
105
초록▼
The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma
The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
대표청구항▼
What is claimed is: 1. A sustained release pharmaceutical composition for once a day oral administration comprising about 20% to about 50% by weight of trazodone or a derivative thereof, about 20% to about 50% by weight of cross-linked high amylose starch, about 10% to about 25% by weight of hydrox
What is claimed is: 1. A sustained release pharmaceutical composition for once a day oral administration comprising about 20% to about 50% by weight of trazodone or a derivative thereof, about 20% to about 50% by weight of cross-linked high amylose starch, about 10% to about 25% by weight of hydroxypropylmethylcellulose, about 0% to about 5% by weight of cetylpyridinium chloride, about 0% to about 20% by weight of alginic acid, about 1% to about 5% by weight of sodium stearyl fumarate, and up to about 1% by weight of colloidal silicon dioxide, wherein the composition, when administered orally to a mammal, releases the trazodone or the derivative thereof so as to maintain a substantially constant effective plasma concentration between about 50 ng/mL and about 3000 ng/mL from at least about one hour to at least about 24 hours after initial administration. 2. The sustained release pharmaceutical composition according to claim 1, wherein the plasma concentration is effective at treating depression in the mammal. 3. The sustained release pharmaceutical composition according to claim 1, wherein the plasma concentration is effective at treating a sleep disorder in the mammal. 4. The sustained release pharmaceutical composition according to claim 1, wherein the composition comprises 150 mg of trazodone hydrochloride. 5. The sustained release pharmaceutical composition according to claim 4, wherein the plasma trazodone concentration achieved one hour after ingestion is between about 150 ng/mL and about 500 ng/mL. 6. The sustained release pharmaceutical composition according to claim 1, wherein the composition comprises 300 mg of trazodone hydrochloride. 7. The sustained release pharmaceutical composition according to claim 6, wherein the plasma trazodone concentration one hour after ingestion is between about 300 ng/mL and about 1000 ng/mL. 8. The sustained release pharmaceutical composition according to claim 1, wherein the composition comprises from about 35% to 50% by weight percent trazodone hydrochloride. 9. The sustained release pharmaceutical composition according to claim 1, wherein the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride. 10. The sustained release pharmaceutical composition according to claim 9, wherein the cross-linked high amylose starch comprises hydroxypropyl side chains. 11. The sustained release pharmaceutical composition according to claim 10, wherein the cross-linked high amylose starch is gelatinized. 12. The sustained release pharmaceutical composition according to claim 1, wherein the mammal is a human. 13. The sustained release pharmaceutical composition according to claim 1, wherein the composition is in the form of a tablet. 14. The sustained release pharmaceutical composition according to claim 13, wherein the tablet is shaped in the form of a caplet. 15. The sustained release pharmaceutical composition according to claim 14, wherein the caplet comprises about 300 mg trazodone. 16. The sustained release pharmaceutical composition according to claim 1, which is adapted for administration before bedtime. 17. The sustained release pharmaceutical composition according to claim 16, wherein the composition provides substantially no drowsiness in a person about 8 hours after oral administration relative to repeated administrations of an immediate release trazodone composition. 18. A method of treating a sleeping disorder comprising administering to a person with the sleeping disorder a sustained release pharmaceutical composition of claim 1. 19. The method according to claim 18, wherein the disorder is treated to improve sleep architecture. 20. The method according to claim 19, wherein the composition is administered before bedtime. 21. A method of treating depression comprising administering once a day to a person with depression a sustained release pharmaceutical composition according to claim 1. 22. The method according to claim 21, wherein the composition is administered before bedtime. 23. The sustained release formulation according to claim 1, wherein the trazodone derivative is trazodone hydrochloride.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (105)
Shah Shirish A. ; Ho Chris Y., Acetaminophen sustained-release formulation.
Kolter, Karl; Schonherr, Michael; Ascherl, Hermann, Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production.
Miller Ronald B. (Basel CHX) Leslie Stewart T. (Cambridge GB2) Malkowska Sandra T. A. (Cambridgeshire GB2) Smith Kevin J. (Cambridge GB2) Wimmer Walter (Limburg DEX) Winkler Horst (Linter DEX) Hahn U, Controlled release formulation.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Johannes Heinrich Bartholomaeus DE; Iris Ziegler DE, Controlled release tramadol preparation with a storage-stable release profile and process for their production.
Cartilier Louis (Beaconsfield CAX) Mateescu Mircea A. (Verdun CAX) Dumoulin Yves (Ste-Julie CAX) Lenaerts Vincent (Paris FRX), Cross-linked amylose as a binder/disintegrant in tablets.
Mateescu Mircea A. (Verdun CAX) Dumoulin Yves (Ste-Julie CAX) Cartilier Louis (Beaconsfield CAX) Lenaerts Vincent (Argenteuil CAX), Cross-linked enzymatically controlled drug release.
Lenaerts, Vincent; Beck, Roland Herwig Friedrich; Van Bogaert, Elsie; Chouinard, Francois; Hopcke, Reiner; Desevaux, Cyril, Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture.
Vincent Lenaerts CA; Francois Chouinard CA; Mircea Alexandru Mateescu CA; Pompilia Ispas-Szabo CA, Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents.
Lenaerts Vincent,CAX ; Chouinard Francois,CAX ; Mateescu Mircea Alexandru,CAX ; Ispas-Szabo Pompilia,CAX, Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds.
Dumoulin Yves,CAX ; Carriere Fran.cedilla.ois,CAX ; Ingenito Andre,CAX, Manufacture of cross-linked amylose useful as a excipient for control release of active compounds.
Sackler Richard S. (Greenwich CT) Kaiko Robert F. (Weston CT) Goldenheim Paul (Wilton CT), Method of treating pain by administering 24 hour oral opioid formulations.
Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
Radebaugh Galen W. (Maple Glen PA) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release acetaminophen formulation and process.
Radebaugh Galen W. (Maple Glen PA) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release acetaminophen formulation and process.
Radebaugh Galen W. (Chester NJ) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release pharmaceutical formulation and process.
Hirsh, Jane; Midha, Kamal; Hirsh, Mark; Lo, Whe-Yong, Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration.
Chouinard Francois,CAX ; Jacques Wilfrid,CAX, Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcell.
Ronald Brown Miller CH; Stewart Thomas Leslie GB; Sandra Therese Antoinette Malkowska GB; Derek Allan Prater GB; Trevor John Knott GB; Hassan Mohammad GB, Pharmaceutical formulation.
Conte Ubaldo,ITX ; Maggi Lauretta,ITX, Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids.
Vanderhoff John W. ; Lu Cheng Xun ; Lee Clarence C. ; Tsai Chi-Chun, Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained.
Lerman Ori (Ramat Gan ILX) Tennenbaum Michael (Rosh Haayin ILX) Gal Erez (Givataim ILX) Kaspi Joseph (Givataim ILX), Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts.
Lerman Ori,ILX ; Kaspi Joseph,ILX ; Brenner Dov,ILX, Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride.
Cherkez Stephen (Ramat Gan ILX) Lerman Ori (Ramat Gan ILX) Tennenbaum Michael (Kiryat Ono ILX) Avner Hasalia (Ashdod ILX) Kunyevski Tamar (Rehovot ILX), Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts.
Roser, Bruce J.; Colaco, Camilo; Jerrow, Mohammed A. Z.; Blair, Julian; Kampinga, Jaap; Wardell, James Lewis; Duffy, John Alistair, Solid delivery systems for controlled release of molecules incorporated therein and methods of making same.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release formulations having acrylic polymer coating.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin ; Chasin Mark ; Pedi ; Jr. Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack Benjamin ; Pedi ; Jr. Frank ; Chasin Mark, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Derrieu Guy (Cagnes sur Mer FRX) Raynier Bernard (Nice FRX), Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications.
Valentine William (Lawrenceville GA) Valentine William K. (Lawrenceville GA), Sustained release composition and method utilizing xanthan gum and an active ingredient.
Patel Satischandra P. (Livingston NJ) Bhalani Vinayak T. (Morris Plains NJ), Sustained release composition for oral administration of active ingredient.
Heafield Joanne,GBX ; Knott Trevor John,GBX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Miller Ronald Brown,CHX ; Prater Derek Allan,GBX ; Smith Kevin John,GBX, Sustained release compositions and a method of preparing pharmaceutical compositions.
Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
Christoph, Thomas; Friderichs, Elmar, Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol.
Mateescu Mircea A. (Verdun CAX) Lenaerts Vincent (Brossard CAX) Dumoulin Yves (Boucherville CAX), Use of cross-linked amylose as a matrix for the slow release of biologically active compounds.
Gervais, Sonia; Smith, Damon; Rahmouni, Miloud; Contamin, Pauline; Ouzerourou, Rachid; Ma, My Linh; Ferrada, Angela; Soulhi, Fouzia, Trazodone composition for once a day administration.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.